牛胎盘提取物通过增强肠道屏障,改善免疫功能和恢复肠道微生物群来改善环胺诱导的肠道损伤
Yuquan Zhao1, Zeru Zhang1, Anguo Tang1
1The Key Laboratory of Animal Disease and Human Health of Sichuan Province, The Medical Research Center for Cow Disease, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China.
Veterinary sciences
|October 25, 2024
概括
牛胎盘提取物 (CPE) 保护小鼠免受环胺诱导的肠损伤. CPE增强了肠道屏障功能,增强了免疫反应,并恢复了肠道微生物群的平衡,提供了一个潜在的治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫抑制会损害肠道屏障的完整性.
- 牛胎盘提取物 (CPE) 含有具有免疫调节和抗氧化特性的.
- 环胺 (Cy) 是一种化疗剂,可以诱导免疫抑制和肠道损伤.
研究的目的:
- 在免疫抑制小鼠中研究CPE对Cy诱导的肠损伤的预防作用.
- 评估CPE对肠道屏障功能,免疫反应和肠道微生物群的影响.
主要方法:
- 三十六只小鼠被分为控制,模型 (Cy-treated) 和CPE治疗组.
- CPE是每天通过输液给药,Cy是每天给药,在过去的三天内是腹膜内给药.
- 分析了肠道屏障功能标志物 (d-乳酸盐,DAO,奥克卢丁,ZO-1,MUC-2),免疫参数 (器官指数,sIgA,SOD,细胞因子) 和肠道微生物群组成.
主要成果:
- CPE显著降低了血清d-乳酸盐和二胺氧化酶活性,表明肠道屏障功能得到改善.
- CPE增加了紧结蛋白 (Occludin,ZO-1) 和Mucin-2的表达.
- CPE增强了免疫器官指数,分泌IgA,SOD,以及调节的促炎和抗炎细胞因子 (IL-1β,IL-4,IL-10,TNF-α).
- CPE改善了肠道微生物群的多样性,并增加了诸如Candidatus_Saccharimonas,Psychrobacter和Enterorhabdus等有益细菌的丰富性.
结论:
- 牛胎盘提取物有效地改善了小鼠的环胺诱导的肠损伤.
- 通过加强肠道屏障,调节免疫功能,恢复肠道微生物群的恒常性,CPE发挥其保护作用.
- CPE显示出作为一种治疗药物的潜力,用于治疗化疗引起的胃肠道并发症.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Drugs for Treatment of Ulcerative Colitis in IBD
124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
362
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
362


